Cargando…

Glial Cell Expression of PD-L1

The programmed death (PD)-1/PD-L1 pathway is a well-recognized negative immune checkpoint that results in functional inhibition of T-cells. Microglia, the brain-resident immune cells are vital for pathogen detection and initiation of neuroimmune responses. Moreover, microglial cells and astrocytes g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauhan, Priyanka, Lokensgard, James R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479336/ https://www.ncbi.nlm.nih.gov/pubmed/30987269 http://dx.doi.org/10.3390/ijms20071677

Ejemplares similares

Glial cells suppress postencephalitic CD8(+) T lymphocytes through PD‐L1
por: Schachtele, Scott J., et al.
Publicado: (2014)

The PD-1: PD-L1 pathway promotes development of brain-resident memory T cells following acute viral encephalitis
por: Prasad, Sujata, et al.
Publicado: (2017)

Reactive glia promote development of CD103(+)CD69(+) CD8(+) T‐cells through programmed cell death‐ligand 1 (PD‐L1)
por: Prasad, Sujata, et al.
Publicado: (2018)

Modulation of Microglial Cell Fcγ Receptor Expression Following Viral Brain Infection
por: Chauhan, Priyanka, et al.
Publicado: (2017)

Glial cell activation, recruitment, and survival of B-lineage cells following MCMV brain infection
por: Lokensgard, James R., et al.
Publicado: (2016)

Regulatory T-Cells Suppress Cytotoxic T Lymphocyte Responses against Microglia
por: Chauhan, Priyanka, et al.
Publicado: (2022)

Dysregulated Microglial Cell Activation and Proliferation Following Repeated Antigen Stimulation
por: Prasad, Sujata, et al.
Publicado: (2021)

Recall Responses from Brain-Resident Memory CD8(+) T Cells (bT(RM)) Induce Reactive Gliosis
por: Prasad, Sujata, et al.
Publicado: (2019)

PD-L1 Expression in Mastocytosis
por: Williams, Margaret, et al.
Publicado: (2019)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Dysregulated brain regulatory T cells fail to control reactive gliosis following repeated antigen stimulation
por: Prasad, Sujata, et al.
Publicado: (2023)

PD-L1: expression regulation
por: Zhou, Yu-Jie, et al.
Publicado: (2023)

Antiallodynic Effects of Cannabinoid Receptor 2 (CB(2)R) Agonists on Retrovirus Infection-Induced Neuropathic Pain
por: Sheng, Wen S., et al.
Publicado: (2019)

Nitrosative damage during retrovirus infection-induced neuropathic pain
por: Chauhan, Priyanka, et al.
Publicado: (2018)

Differential Cytokine-Induced Responses of Polarized Microglia
por: Chauhan, Priyanka, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
por: Yokoyama, Shintaro, et al.
Publicado: (2020)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies
por: Mucileanu, Adrian, et al.
Publicado: (2021)

Regulation of PD-L1 expression in the tumor microenvironment
por: Yi, Ming, et al.
Publicado: (2021)

Regulation of PD-L1 Expression by Nuclear Receptors
por: Kiriyama, Yoshimitsu, et al.
Publicado: (2023)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
por: Kammerer-Jacquet, Solène-Florence, et al.
Publicado: (2019)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

PD-L1 expression testing in non-small cell lung cancer
por: Teixidó, Cristina, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice
por: Hirose, Takayuki, et al.
Publicado: (2017)

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
por: Wang, Tao, et al.
Publicado: (2022)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Aung, Phyu P., et al.
Publicado: (2019)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fs912agk21k88m5diqg63n6ukl